Labroots’ virtual events are a fantastic way to network and learn about the work of other researchers in your field. These events feature participants from around the world who can showcase their ...

STOUGHTON, Mass.--(BUSINESS WIRE)--Shields Health Solutions (Shields), the premier specialty pharmacy accelerator in the country, announced today that it will host a session titled “The Evolution of ...

TRS is always an amazing highlight of the hard work and talent among our trainees in basic science and clinical research. For this year’s poster presentation, abstracts were submitted by undergraduate ...

BELTSVILLE, Md., Nov. 07, 2022 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class ...

Autumn Spyhalsky, PharmD/MS’24, received the Best Student Poster Award for her poster titled Dynamics of Urinary Biomarkers to Detect Acute Kidney Injury in Critically Ill Children Receiving ...

RALEIGH, N.C., Dec. 04, 2025 (GLOBE NEWSWIRE) -- Parexel, a leading global clinical research organization (CRO) providing insights-driven Clinical and Consulting solutions to the world’s life sciences ...

‒ The GP2 Phase III clinical trial design was presented during the 2020 San Antonio Breast Cancer Symposium (SABCS) and introduced by the Global Principal Investigator, Professor Mothaffar F. Rimawi ...

At the 2024 Educational Research and Innovations in Clinical and Health Sciences (ENRICH) Week poster session, Hunter “Caroline” Davies secured first place in the innovation category for her poster, ...

Labroots is excited to host the 16th Annual Clinical Diagnostics & Research Virtual Event Series on November 12, 2025. This premier online event unites clinicians, lab professionals, and researchers ...

BOSTON, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (TLSA) (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies ...

Tuspetinib (TUS), being developed by Aptose and originally created by Hanmi Pharmaceutical Co., is being advanced as the TUS+VEN+AZA triplet (tuspetinib+venetoclax+azacitidine) for frontline therapy ...